Pulmonary Surfactant

The problem surfactant solves

Every alveolus is a tiny air sac lined by a thin film of water. Wherever water meets air, the water molecules at the surface pull on one another more strongly than they pull on the air above, creating surface tension — the same force that lets an insect stand on a pond and that pulls a soap bubble inward. In a curved surface like an alveolus, that tension generates a pressure that tries to shrink the sac and squeeze the air out. Pure water has a surface tension of about 70 millinewtons per meter (mN/m). If the 300 million alveoli of an adult lung were lined with plain water, the collapsing pressures would be so large that the lungs would be almost impossible to inflate and would empty themselves at every exhalation.

The physics is captured by the Law of Laplace. For a sphere with one liquid-air interface, the collapsing pressure is

P = 2T / r

where P is the inward pressure, T is the surface tension, and r is the radius. The crucial term is the radius in the denominator: for a given surface tension, a smaller alveolus generates a larger collapsing pressure. That is profoundly destabilizing. If two alveoli of different size shared an airway and had the same surface tension, the small one — with its higher internal pressure — would empty itself into the larger one, and the lung would devolve into a few giant, useless sacs surrounded by collapsed tissue. Surfactant is the molecular trick that makes the alveolus a stable structure despite this physics.

What surfactant is made of

Surfactant is a surface-active agent — a detergent, in the loosest sense. It is roughly 90% lipid and 10% protein by weight. The dominant molecule is dipalmitoylphosphatidylcholine (DPPC), a phospholipid with two saturated fatty-acid tails that make up something like 40–50% of the total mass. Like all phospholipids, DPPC is amphipathic: its phosphate head loves water while its fatty tails repel it. Floated onto the alveolar lining, these molecules orient with their heads in the water and their tails sticking up into the air, forming a single tightly packed monolayer right at the air-liquid interface.

That monolayer is what lowers surface tension. By inserting themselves between the water molecules at the surface, the lipid tails disrupt the cohesive pull that water has on itself. The more densely the molecules pack, the weaker that pull becomes — and DPPC's straight saturated tails pack extraordinarily tightly, which is why it can drive surface tension down toward zero when compressed. The remaining lipids, including unsaturated phospholipids and a small amount of cholesterol, keep the film fluid enough to spread and re-spread with each breath.

The protein fraction is small but essential. Four surfactant proteins share the work, in two functional pairs:

• SP-B and SP-C are small, intensely hydrophobic proteins. They are the mechanical engineers of the film — they speed the adsorption of fresh lipid to the surface, help DPPC spread evenly, and enable the film to be compressed and re-expanded thousands of times a day. Hereditary loss of SP-B is lethal in newborns even at full term, underscoring how indispensable it is.
• SP-A and SP-D are large, water-soluble proteins of the collectin family. They contribute relatively little to the mechanics and instead serve innate immunity: they bind carbohydrate patterns on bacteria, viruses, and fungi, flag them for clearance (opsonization), and tune the responses of alveolar macrophages. SP-A also helps regulate the recycling of surfactant.

Where it comes from and how it cycles

Surfactant is manufactured by the type II pneumocyte, a cuboidal cell that is numerically common — about 60% of alveolar cells — yet covers only around 5% of the alveolar surface, because the thin, flat type I cells handle the actual gas exchange. The type II cell assembles surfactant components in the endoplasmic reticulum and packages them into dense, onion-layered organelles called lamellar bodies. When the cell is stretched or stimulated, it secretes these lamellar bodies into the thin layer of fluid lining the alveolus. There the lipid unspools into a lattice called tubular myelin and then adsorbs to the air-liquid interface to form the working monolayer.

The film is not static. As the alveolus shrinks during exhalation, the monolayer is compressed, packing the DPPC molecules ever more tightly and squeezing surface tension down to near zero — precisely when the collapsing radius is smallest and the lung needs the most help. As the alveolus expands during inhalation, the film spreads thinner and surface tension rises again, which actually aids the elastic recoil that will drive the next exhalation. This dynamic, surface-area-dependent tension is the heart of how surfactant stabilizes alveoli of unequal size. Old surfactant is taken back up by type II cells and macrophages, broken down, and largely recycled; the entire alveolar pool turns over on the order of hours.

The numbers that matter

Surfactant's mechanical payoff is large and measurable. It pushes alveolar surface tension from the ~70 mN/m of pure water down to roughly 25 mN/m at rest and near 0–5 mN/m at end-expiration. That translates into a two- to four-fold increase in lung compliance (the ease with which the lung inflates for a given pressure) and a comparable reduction in the work of breathing. Just as importantly, by keeping interfacial tension low, surfactant keeps the alveoli dry: high surface tension would generate a negative interstitial pressure that sucks fluid out of the pulmonary capillaries, so a failing surfactant film promotes alveolar edema.

In fetal development the timing is everything. Type II cells begin limited surfactant synthesis around 24–28 weeks of gestation, but a robust, mature surfactant pool generally does not appear until about 35 weeks. The classic bedside marker of lung maturity is the lecithin-to-sphingomyelin (L/S) ratio measured in amniotic fluid: a value above 2.0 signals that enough surfactant is present, while a lower ratio predicts neonatal respiratory distress.

Clinical correlations: RDS and ARDS

The most direct disease of surfactant is neonatal respiratory distress syndrome (RDS), formerly called hyaline membrane disease. A premature baby whose type II cells have not yet made enough surfactant is born with stiff, non-compliant lungs. Alveoli collapse at end-expiration, the infant must generate enormous negative pressures to reinflate them with each breath, and the work of breathing quickly becomes unsustainable — producing grunting, retractions, nasal flaring, and progressive hypoxemia within hours of birth. The chest X-ray shows a diffuse "ground-glass" haze with air bronchograms. Management is one of the great success stories of modern neonatology: antenatal corticosteroids given to the mother accelerate fetal type II cell maturation, and exogenous surfactant (animal-derived preparations such as poractant alfa or beractant) instilled directly into the trachea after birth, alongside CPAP or mechanical ventilation, has dramatically reduced mortality.

In adults, surfactant is rarely absent but is often inactivated. In acute respiratory distress syndrome (ARDS), an inflammatory insult — sepsis, aspiration, pneumonia, trauma, or pancreatitis — damages the alveolar-capillary barrier. Protein-rich edema fluid floods the airspaces, and plasma proteins such as albumin and fibrinogen compete with surfactant lipids for the air-liquid interface, poisoning the film. The type II cells that make and recycle surfactant are themselves injured. The result mimics the mechanics of RDS — stiff lungs, collapsing alveoli, refractory hypoxemia — but the underlying lesion is different, which is why the same exogenous-surfactant therapy that rescues newborns has repeatedly failed to help adults with ARDS.

Neonatal RDS vs adult ARDS — both surfactant failure, different mechanisms

Feature	Neonatal RDS	Acute respiratory distress syndrome (ARDS)
Core problem	Primary surfactant deficiency (too little made)	Secondary surfactant dysfunction (inactivated, plus ongoing injury)
Typical trigger	Prematurity (immature type II cells)	Sepsis, aspiration, pneumonia, trauma, pancreatitis
Type II cells	Immature, not yet producing	Present but injured by inflammation
Surface tension	High — film never forms properly	High — film inactivated by leaked plasma proteins
Lung mechanics	Low compliance, diffuse atelectasis	Low compliance, heterogeneous collapse and edema
Exogenous surfactant	Highly effective, standard of care	Not reliably effective in trials
Adjunct therapy	Antenatal steroids, CPAP, gentle ventilation	Lung-protective low-tidal-volume ventilation, treat cause

Surfactant function is also degraded in other settings. Smoking and meconium aspiration inactivate the film; pneumonia consumes and disrupts it; and rare inherited mutations in SFTPB (SP-B) or SFTPC (SP-C), or in the lipid-transport gene ABCA3, cause interstitial lung disease and lethal neonatal surfactant deficiency despite a full-term birth.

Common misconceptions

• "Surfactant increases surface tension to hold the alveolus open." The opposite — it lowers surface tension, reducing the collapsing pressure that would otherwise empty the sac.
• "Surfactant makes all alveoli the same size." It stabilizes alveoli of different sizes by varying its tension with surface area, so a small alveolus develops lower tension and does not drain into a larger one.
• "Giving surfactant cures adult ARDS the way it cures newborn RDS." In ARDS the existing surfactant is inactivated and the producing cells are injured; replacement therapy has not shown reliable benefit in adults.
• "Surfactant is purely mechanical." SP-A and SP-D give it a genuine innate-immune role, binding and clearing pathogens at the alveolar surface.
• "Type II cells do the gas exchange because there are so many of them." Type II cells are numerous but cover only ~5% of the surface; the flat type I cells handle gas exchange.

This is educational content, not medical advice. For any clinical concern, consult a qualified healthcare professional.